Hemogenyx Pharmaceuticals PLC (HEMO)

ORD GBP0.01

Sell: 580.00p|Buy: 614.00p|Change: 12.00 (2.01%)

Open

616.00p

Previous close

598.00p

Trade high

616.00p

Volume

41,119

Year high

1,800.00p

Year low

124.00p

Dividend yield

–

Market capitalisation

£36.85 mn

P/E ratio

–

ISIN

GB00BQVXM815

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 19/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Hemogenyx Pharmaceuticals PLC	- 7.00
More...

Company profile

Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of innovative treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments.

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
22/12/2025	03:00:47	610	12	73.20
22/12/2025	03:00:47	578	4	23.12
22/12/2025	03:00:47	610	3	18.30
22/12/2025	03:00:47	578	11	63.58
22/12/2025	03:00:47	610	1	6.10

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.